ZSZahra Arab Sadeghabadi

Zahra Arab Sadeghabadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zahra Arab Sadeghabadi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Interaction Between Interleukin-29 and Toll-Like Receptor-4 in the Peripheral Blood Mononuclear Cells of Patients With Type 2 Diabetes

    by Zahra Arab Sadeghabadi, Ameneh Zamani Sedehi, Keihan Ghatreh Samani, Ali Momeni, Roohollah Mohseni

    Background and aims: The Toll-like receptor-4 (TLR-4) signaling pathway and its interaction with cytokines are involved in insulin resistance (IR) progression, primarily through activating adipose tissue macrophages. Interleukin-29 (IL-29) has been suggested as a potential contributor to IR. Therefore, this study aimed to assess the relationship between TLR-4 and IL-29 expression alterations in the peripheral blood mononuclear cells of newly diagnosed type 2 diabetes (T2D) patients. Methods: Overall, 60 participants were enrolled, comprising equal numbers of newly diagnosed T2D patients and healthy controls. Quantitative real-time polymerase chain reaction was employed to determine the messenger RNA expression levels of toll-like receptor-4 (TLR-4), interleukin (IL)-29, TIR-domain-containing adapter-inducing interferon-β (TRIF), and interferon regulatory factor 3 (IRF3). Moreover, serum IL-29 concentrations were quantified using an enzyme-linked immunosorbent assay. Data were analyzed through SPSS 16. In addition, an independent-sample t-test was used to compare the data between the two groups. Ultimately, the relationship between variables was assessed using Pearson’s correlation coefficient. Results: Overall, IL-29 serum levels were significantly increased in the T2D group compared to the control group (P<0.001). Additionally, the gene expression levels of IL-29, TLR4, TRIF, and IRF3 were markedly upregulated in T2D patients relative to healthy individuals (P<0.001). Conclusion: These findings revealed that IL-29 overexpression is linked to the activation of the TLR-4 pathway, which may contribute to the pathogenesis of IR in T2D.

  • AMP‐activated protein kinase is a key regulator of obesity‐associated factors

    by Roohollah Mohseni, Maryam Teimouri, Mohsen Safaei, Zahra Arab Sadeghabadi

    An imbalance between caloric intake and energy expenditure leads to obesity. Obesity is an important risk factor for the development of several metabolic diseases including insulin resistance, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular disease. So, controlling obesity could be effective in the improvement of obesity‐related diseases. Various factors are involved in obesity, such as AMP‐activated protein kinases (AMPK), silent information regulators, inflammatory mediators, oxidative stress parameters, gastrointestinal hormones, adipokines, angiopoietin‐like proteins, and microRNAs. These factors play an important role in obesity by controlling fat metabolism, energy homeostasis, food intake, and insulin sensitivity. AMPK is a heterotrimeric serine/threonine protein kinase known as a fuel‐sensing enzyme. The central role of AMPK in obesity makes it an attractive molecule to target obesity and related metabolic diseases. In this review, the critical role of AMPK in obesity and the interplay between AMPK and obesity‐associated factors were elaborated.


  • Open Access

    Angiopoietin‐Like Proteins 2 and 3 in Children and Adolescents with Obesity and Their Relationship with Hypertension and Metabolic Syndrome

    by Zahra Arab Sadeghabadi, Mitra Nourbakhsh, Mohammad Alaee, Mona Nourbakhsh, Seyedeh Sara Ghorbanhosseini, Roya Sharifi, Maryam Razzaghy-Azar

    Background . Angiopoietin‐like protein 2 (ANGPTL2) is one of the adipocyte‐derived inflammatory factors which connects obesity to insulin resistance. ANGPTL3 has a direct role in regulation of lipid metabolism. The objective of this study was to evaluate ANGPTL2 and ANGPTL3 in childhood obesity and their relationship with metabolic syndrome. Methods . 70 children and adolescents, 35 obese and 35 normal‐weight subjects, were enrolled in this research after complete clinical examination and anthropometric evaluations. Serum ANGPTL2 and ANGPTL3 and insulin were measured by enzyme‐linked immunosorbent assay (ELISA). Homeostatic model assessment of insulin resistance (HOMA‐IR) was calculated and used to estimate insulin resistance (IR). Colorimetric methods were used for the assessment of fasting plasma glucose (FPG), LDL‐C, HDL‐C, total cholesterol (TC), and triglyceride (TG). Results . The levels of ANGPTL2 and ANGPTL3 were significantly higher in obese subjects than those in controls, but they did not differ significantly in subjects with or without IR. ANGPTL3 was found to be significantly elevated in obese children with metabolic syndrome (MetS) in comparison with those without MetS. Both of the studied ANGPTLs were positively correlated with BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), TC, and LDL‐C. The correlation between ANGPTL3 and either TC or LDL‐C remained significant after adjusting for BMI. Conclusion . Serum ANGPTL2 and ANGPTL3 were elevated in obesity and associated with blood pressure and indices of metabolic syndrome, suggesting that they might be involved in the advancement of obesity‐related hypertension and metabolic syndrome.


  • Therapeutic effects of Chlorella vulgaris on carbon tetrachloride induced liver fibrosis by targeting Hippo signaling pathway and AMPK/FOXO1 axis

    by Roohollah Mohseni, Seyed Moayed Alavian, Zahra Arab Sadeghabadi, Mohammad Heiat

    This study was conducted to present the mechanism of the therapeutic effects of Chlorella vulgaris extract (CV) on the carbon tetrachloride (CCl4) induced liver fibrosis model. Primarily, the mechanism of antioxidant effects of CV were investigated via measuring the expression of forkhead box protein O1 (FOXO1) and phosphorylated 5′ adenosine monophosphate-activated protein kinase (p-AMPK) as upstream regulators of superoxide dismutase (SOD) and catalase (CAT). Subsequently, we investigated the regulatory effect of CV treatment on the yes-associated protein (YAP) and transcriptional coactivators with a PDZ-binding motif (TAZ) as fibrogenic factors. Male Wistar rats received CCl4 and olive oil solution 1 ml/kg intraperitoneally for 12 weeks, twice weekly. CV 50 and 100 mg/kg were administered on a daily basis by gavage in the last 4 weeks. Ultimately, liver marker enzymes and hepatic hydroxyproline content were measured. The activity of SOD and CAT and the expression of YAP, TAZ, FOXO1, SOD, and CAT were analyzed. Finally, the protein levels of YAP, TAZ, and p-AMPK were detected. CV administration decreased liver marker enzymes and hydroxyproline content significantly. The expression and protein levels of YAP and TAZ reduced by CV treatment. Furthermore, the augmentation of expression and function of CAT and SOD by CV treatment was followed by an increase in the expression of FOXO1 and protein level of p-AMPK. Our data revealed that the stimulation of expression and function of SOD and CAT by CV treatment could be mediated by FOXO1/p-AMPK axis. Moreover, anti-fibrotic effect of CV might be associated with its inhibitory effect on the hepatic expression of YAP and TAZ. Graphic Abstract Chlorella vulgaris treatment ameliorates liver fibrosis via two cellular mechanisms. A) Likely, Chlorella vulgaris treatment increases gene expression of enzymatic antioxidants superoxide dismutase (SOD) and catalase (CAT) via upregulating its upstream regulatory elements i.e. phosphorylated 5′ adenosine monophosphate-activated protein kinase (p-AMPK) and forkhead box protein O1 (FOXO1). These possible regulatory effects maybe lead to reduce reactive oxygen species level (ROS). B) Chlorella vulgaris treatment decreases hepatic protein level and gene expression of key elements of Hippo signaling pathway i.e. Yes-associated protein (YAP) and Transcriptional coactivators with a PDZ-binding motif (TAZ). Figure created with BioRender (https://biorender.com). ROS: Reactive oxygen species, YAP: Yes-associated protein, TAZ: Transcriptional coactivators with a PDZ-binding motif, FOXO1: Fork head Box O1, AMPK: 5′ adenosine monophosphate activated protein kinase, SOD: Superoxide dismutase, CAT: Catalase, P: Phosphate group.


  • Open Access

    Oral Administration of Resveratrol-Loaded Solid Lipid Nanoparticle Improves Insulin Resistance Through Targeting Expression of SNARE Proteins in Adipose and Muscle Tissue in Rats with Type 2 Diabetes

    by Roohollah Mohseni, Zahra ArabSadeghabadi, Nasrin Ziamajidi, Roghayeh Abbasalipourkabir, Azam RezaeiFarimani

    In the current study, we developed resveratrol (RES)-loaded solid lipid nanoparticle (SLN-RES) in order to improve insulin resistance through the upregulation of SNARE protein complex in rats with type 2 diabetes. The SLN-RES characteristics include the following: the average size of 248 nm, the zeta potential of − 16.5 mV, and 79.9% RES entrapment efficiency. The release profile of SLN-RES showed an initial burst followed by a sustained release in natural condition. Infrared spectroscopy results revealed good incorporation of RES into core SLN. Spherical nanoparticle with less aggregation was observed under electronic microscopic examination. Oral administration of SLN-RES prevented weight loss and showed better hypoglycemic effect than RES. Serum oxidative stress status was restored to the normal level by SLN-RES. Furthermore, expression of synaptosomal-associated protein 23 (Snap23), syntaxin-4 (Stx4), and vesicle-associated membrane protein 2 (Vamp2) as the major elements of SNARE protein complex were reduced by SLN-RES more significantly than RES treatment in muscle tissue. However, SLN-RES has a similar effect to RES treatment in adipose tissue. Taken together, our results revealed SLN-RES could be a modern and interestingly therapeutic approach for the improvement of insulin resistance through targeting the expression of Snap23, Stx4, and Vamp2 in adipose and muscle tissues.